Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
NCT05463224 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2026-04-28
Summary
The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.
Conditions
Interventions
- DRUG
-
Lazertinib group
Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
Sponsors & Collaborators
-
Se-Hoon Lee
lead OTHER
Principal Investigators
-
Se-Hoon Lee, MD · Samsung Medical Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-04
- Primary Completion
- 2026-12-01
- Completion
- 2027-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.
NCT05326425 ·Status: UNKNOWN ·Phase: PHASE2
-
Lazertinib 160mg in EGFR T790M NSCLC
NCT05701384 ·Status: UNKNOWN ·Phase: PHASE2
-
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
NCT05377788 ·Status: UNKNOWN
-
Early Access Program of Lazertinib in Republic of Korea
NCT04829422 ·Status: APPROVED_FOR_MARKETING
-
The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
NCT05167851 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
NCT06268210 ·Status: RECRUITING ·Phase: PHASE2
-
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
NCT06020989 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
NCT01776684 ·Status: UNKNOWN ·Phase: NA
-
Uncommon EGFR AZD9291
NCT03424759 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
NCT04248829 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
NCT05786430 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
NCT06062823 ·Status: RECRUITING ·Phase: PHASE2
-
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
NCT06156527 ·Status: RECRUITING ·Phase: PHASE2
-
Impact of Lazertinib Dose Modification on Effectiveness and Safety
NCT05716672 ·Status: NOT_YET_RECRUITING
-
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
NCT06106802 ·Status: RECRUITING ·Phase: PHASE2
-
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
NCT02431169 ·Status: TERMINATED
-
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 ·Status: UNKNOWN
-
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
NCT03721289 ·Status: COMPLETED
-
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
NCT06893354 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
NCT02450591 ·Status: COMPLETED ·Phase: NA
-
Acquired Resistant Mechanism of the First-generation EGFR TKIs
NCT02804217 ·Status: UNKNOWN
-
Study of Lorlatinib in ROS1 Rearranged NSCLC
NCT03612154 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
NCT02738684 ·Status: UNKNOWN
-
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
NCT05466149 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
NCT01470716 ·Status: UNKNOWN ·Phase: PHASE2